Veru's VERU-111 Moves Into Pivotal COVID-19 Study

Veru Inc (NASDAQ: VERUwill start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distress Syndrome.

  • Mitchell Steiner, chairman, president, and CEO, said, "we have the resources to conduct a Phase 3 trial without impacting our cancer drugs' clinical development."
  • Recently, the company raised gross proceeds of approximately $100 million via secondary equity offering.
  • The company will seek funding from The Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services.
  • The 400-subject Phase 3 study will evaluate daily oral doses of VERU-111 versus placebo with the primary efficacy endpoint of the proportion of patients alive at Day 29.
  • The trial will start next month and results expected by the end of this year.
  • Price Action: VERU shares are trading 2.75% higher at $14.20 on the last check Monday.

Posted In: Acute Respiratory Distress SyndromeCovid-19Phase 3 TrialBiotechNewsHealth CareSmall CapFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.